[Is one antihypertensive agent as good as another?].
作者信息
Trenkwalder Peter
机构信息
Medizinische Klinik Klinikum Starnberg Osswaldstr. 1, 82319 Starnberg.
出版信息
MMW Fortschr Med. 2002 Nov 7;144(45):41-2.
PMID:12534060
Abstract
摘要
相似文献
1
[Is one antihypertensive agent as good as another?].
MMW Fortschr Med. 2002 Nov 7;144(45):41-2.
2
[LIFE study proves preventive action. With losartan to do even more against stroke].
MMW Fortschr Med. 2003;145 Suppl 1:7-8.
3
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
MMW Fortschr Med. 2002 Apr 4;144(14):4-5.
4
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
J Hypertens. 2009 Mar;27(3):567-74. doi: 10.1097/HJH.0b013e32831daf96.
5
[Hypertensive patient with enlarged heart. Caution, risk of atrial fibrillation!].
MMW Fortschr Med. 2006 May 25;148(21):62.
6
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Circ Arrhythm Electrophysiol. 2008 Dec;1(5):337-43. doi: 10.1161/CIRCEP.108.795351. Epub 2008 Dec 2.
7
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
MMW Fortschr Med. 2006 Mar 16;148(11):57, 59-60.
8
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435.
9
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Curr Med Res Opin. 2007 Feb;23(2):259-70. doi: 10.1185/030079906X162854.
10
[AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
MMW Fortschr Med. 2006 Mar 30;148(13):48-9.
Zotero 插件